Determination of the Optimal In-Feed Amino Acid Ratio for Japanese Quail Breeders Based on Utilization Efficiency.

The description of the genetic potential is the first step to estimating amino acid requirements and the ideal amino acid relation (IAAR). The aim of this study was to estimate the parameters that describe the daily maximum theoretical nitrogen retention (NRmaxT, mg/BWkg0.67), daily nitrogen maintenance requirement (NMR, mg/BWkg0.67), protein quality (b), dietary efficiency of the limiting amino acid (bc-1) and determine the lysine requirement and the IAAR for Japanese quail breeders. Two nitrogen balance assays were performed, one assay using 49 quails distributed in seven treatments (protein levels between 70.1 and 350.3 g/kg) and seven replicates and other assay to determine the IAAR by the use of bc-1, 12 treatments and 10 replicate, with a control diet (CD) and 11 treatments that had limited essential amino acids by providing only 60% of the CD. The values obtained for NRmaxT, NMR, b and bc-1 were 3386.61, 0.000486 and 0.000101, respectively. The daily intake of Lys was 291 mg/bird day. Lys was set at 100% for determining the IAAR: 87, 67, 21, 117, 96, 66, 142, 39, and 133 for Met + Cys, Thr, Trp, Arg, Val, Ile, Leu, His, and Phr + Tyr, respectively, for Japanese quail breeders.

Acoustic modulation and photon-phonon scattering in optical coherence tomography.

Acousto-optic interactions allow the measurement of nonoptical material properties with high-resolution optical methods. We modulated a sample with ultrasound while simultaneously imaging with a traditional optical coherence tomography (OCT) system. The measured acousto-optic signal then depends on the mechanical response of the tissue to the applied modulation. The acquired acoustically enhanced OCT signals are consistent with established acousto-optic theory and provide enhanced contrast to OCT images.

A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup.

BACKGROUND: In children with croup, treatment with nebulized budesonide decreases symptoms, but it is uncertain how budesonide compares with dexamethasone, the conventional therapy for croup, and whether either reduces the rate of hospitalization. METHODS: We performed a double-blind, randomized trial involving 144 children with moderately severe croup. The children were treated with racepinephrine and a single dose of 4 mg of nebulized budesonide (48 children), 0.6 mg of intramuscular dexamethasone per kilogram of body weight (47 children), or placebo (49 children). The children were assessed before treatment and then hourly for five hours after treatment. Physicians who were unaware of the treatment assignments determined the children's need for further treatment and hospitalization. RESULTS: The characteristics of the groups were similar at base line, including the types of viruses identified, the types of croup, and the clinical severity of the illness. The overall rates of hospitalization were 71 percent in the placebo group (35 of 49 children), 38 percent in the budesonide group (18 of 48 children), and 23 percent in the dexamethasone group (11 of 47 children) (unadjusted P=0.001 for the comparison of budesonide with placebo, P<0.001 for the comparison of dexamethasone with placebo, and P=0.18 for the comparison of budesonide with dexamethasone). Children treated with budesonide or dexamethasone had a greater improvement in croup scores than those given placebo (P=0.03 and P<0.001, respectively), and those treated with dexamethasone had a greater improvement than those treated with budesonide (P=0.003). CONCLUSIONS: In children with moderately severe croup, treatment with intramuscular dexamethasone or nebulized budesonide resulted in more rapid clinical improvement than did the administration of placebo, with dexamethasone offering the greatest improvement. Treatment with either glucocorticoid resulted in fewer hospitalizations.

Patients' perceptions of outcomes of a Canadian hospitalization.

Notes that with health care reform moving at tremendous speed throughout Canada, a great deal of interest in outcomes research has been generated. States that the research team consisted of 17 professional practice leaders from eight disciplines. Proposes, through the research, to identify from the perspective of former patients what results they hoped to achieve prior to discharge from hospital and what facilitated and hindered them in achieving these results. Reports that a representative sample was selected for the study. Forty-one former patients each participated in up to two focus groups, with a total of 16 focus groups conducted. Hierarchical analysis revealed themes that fell within the framework of structure, process and outcomes. The findings will assist in ensuring that more appropriate and effective care is offered to patients by a variety of disciplines.

Decreased protein binding of salicylates in Kawasaki disease.

Because patients with Kawasaki disease have low serum concentrations of salicylates despite high doses, and because the free (unbound) drug is responsible for the pharmacologic effects of salicylates, we assessed salicylate protein binding in patients with Kawasaki disease. During the acute phase of the disease, protein binding of salicylate in 36 children with Kawasaki disease was 73 +/- 12%, significantly lower than during the subacute phase (90.4 +/- 8.7%; p less than 0.0005). Mean serum albumin concentration was 29.2 +/- 6.4 gm/L during the acute phase and 36.7 +/- 7.8 gm/L during the subsequent subacute phase (p less than 0.005). Salicylate protein binding was affected independently by both serum albumin and total salicylate levels. During the acute phase of Kawasaki disease, children had an average twofold increase in free salicylate compared with normoalbuminemic control subjects. A nomogram has been devised to derive free salicylate levels from the known total salicylate and serum albumin concentrations.